Literature DB >> 24480044

Use of laboratory-based surveillance data to estimate the number of people chronically infected with hepatitis B living in Scotland.

C Schnier1, L Wallace2, K Tempelton3, C Aitken4, R N Gunson4, P Molyneaux5, P McINTYRE6, C Povey7, D Goldberg2, S Hutchinson1.   

Abstract

It is paramount to understand the epidemiology of chronic hepatitis B to inform national policies on vaccination and screening/testing as well as cost-effectiveness studies. However, information on the national (Scottish) prevalence of chronic hepatitis B by ethnic group is lacking. To estimate the number of people with chronic hepatitis B in Scotland in 2009 by ethnicity, gender and age, the test data from virology laboratories in the four largest cities in Scotland were combined with estimates of the ethnic distribution of the Scottish population. Ethnicity in both the test data and the Scottish population was derived using a name-based ethnicity classification software (OnoMAP; Publicprofiler Ltd, UK). For 2009, we estimated 8720 [95% confidence interval (CI) 7490-10 230] people aged ⩾15 years were living with chronic hepatitis B infection in Scotland. This corresponds to 0·2% (95% CI 0·17-0·24) of the Scottish population aged ⩾15 years. Although East and South Asians make up a small proportion of the Scottish population, they make up 44% of the infected population. In addition, 75% of those infected were aged 15-44 years with almost 60% male. This study quantifies for the first time on a national level the burden of chronic hepatitis B infection by ethnicity, gender and age. It confirms the importance of promoting and targeting ethnic minority groups for hepatitis B testing.

Entities:  

Mesh:

Year:  2013        PMID: 24480044      PMCID: PMC9151307          DOI: 10.1017/S0950268813003105

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  15 in total

1.  Overcoming barriers to hepatitis B immunisation by a dedicated hepatitis B immunisation service.

Authors:  V F Larcher; J Bourne; C Aitken; D Jeffries; D Hodes
Journal:  Arch Dis Child       Date:  2001-02       Impact factor: 3.791

2.  Denmark scales up hepatitis B screening and vaccination for risk groups.

Authors:  Susan A Cowan
Journal:  Euro Surveill       Date:  2005-11-03

3.  The importance of imported infections in maintaining hepatitis B in The Netherlands.

Authors:  I K Veldhuijzen; L J M Smits; M J W van de Laar
Journal:  Epidemiol Infect       Date:  2005-02       Impact factor: 2.451

4.  The prevalence of hepatitis B infection in adults in England and Wales.

Authors:  N J Gay; L M Hesketh; K P Osborne; C P Farrington; P Morgan-Capner; E Miller
Journal:  Epidemiol Infect       Date:  1999-02       Impact factor: 2.451

5.  Name analysis to classify populations by ethnicity in public health: validation of Onomap in Scotland.

Authors:  F Lakha; D R Gorman; P Mateos
Journal:  Public Health       Date:  2011-09-09       Impact factor: 2.427

6.  Hepatitis C virus: laboratory surveillance in England and Wales, 1992-2004.

Authors:  U Gungabissoon; M A Balogun; M E Ramsay
Journal:  Epidemiol Infect       Date:  2006-09-06       Impact factor: 2.451

Review 7.  Global epidemiology of hepatitis B virus.

Authors:  Brian Custer; Sean D Sullivan; Thomas K Hazlet; Uchenna Iloeje; David L Veenstra; Kris V Kowdley
Journal:  J Clin Gastroenterol       Date:  2004 Nov-Dec       Impact factor: 3.062

8.  Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B.

Authors:  Maria Buti; Max Brosa; Miguel A Casado; Magdalena Rueda; Rafael Esteban
Journal:  J Hepatol       Date:  2009-05-20       Impact factor: 25.083

9.  Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective.

Authors:  Irene K Veldhuijzen; Mehlika Toy; Susan J M Hahné; G Ardine De Wit; Solko W Schalm; Robert A de Man; Jan Hendrik Richardus
Journal:  Gastroenterology       Date:  2009-10-29       Impact factor: 22.682

10.  The prevalence of hepatitis B and C in an antenatal population of various ethnic origins.

Authors:  E Boxall; S Skidmore; C Evans; S Nightingale
Journal:  Epidemiol Infect       Date:  1994-12       Impact factor: 2.451

View more
  4 in total

1.  Informing the design of a national screening and treatment programme for chronic viral hepatitis in primary care: qualitative study of at-risk immigrant communities and healthcare professionals.

Authors:  Lorna Sweeney; John A Owiti; Andrew Beharry; Kamaldeep Bhui; Jessica Gomes; Graham R Foster; Trisha Greenhalgh
Journal:  BMC Health Serv Res       Date:  2015-03-13       Impact factor: 2.655

2.  Pathology Laboratory Surveillance in the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance of Sexually Transmitted Infections and Blood-Borne Viruses: Protocol for a Cohort Study.

Authors:  Caroline van Gemert; Rebecca Guy; Mark Stoove; Wayne Dimech; Carol El-Hayek; Jason Asselin; Clarissa Moreira; Long Nguyen; Denton Callander; Douglas Boyle; Basil Donovan; Margaret Hellard
Journal:  JMIR Res Protoc       Date:  2019-08-08

Review 3.  Innovative strategies for the elimination of viral hepatitis at a national level: A country case series.

Authors:  Sophia E Schröeder; Alisa Pedrana; Nick Scott; David Wilson; Christian Kuschel; Lisa Aufegger; Rifat Atun; Ricardo Baptista-Leite; Maia Butsashvili; Manal El-Sayed; Aneley Getahun; Saeed Hamid; Radi Hammad; Ellen 't Hoen; Sharon J Hutchinson; Jeffrey V Lazarus; Olufunmilayo Lesi; Wangsheng Li; Rosmawati Binti Mohamed; Sigurdur Olafsson; Raquel Peck; Annette H Sohn; Mark Sonderup; Catherine W Spearman; Tracy Swan; Mark Thursz; Tim Walker; Margaret Hellard; Jessica Howell
Journal:  Liver Int       Date:  2019-09-04       Impact factor: 5.828

4.  Complex differences in infection rates between ethnic groups in Scotland: a retrospective, national census-linked cohort study of 1.65 million cases.

Authors:  L D Gruer; G I Cézard; L A Wallace; S J Hutchinson; A F Douglas; D Buchanan; S V Katikireddi; A D Millard; D J Goldberg; A Sheikh; R S Bhopal
Journal:  J Public Health (Oxf)       Date:  2022-03-07       Impact factor: 5.058

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.